---
title: "MYL released its 2024 annual performance, with a net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234218976.md"
description: "MYL released its 2024 annual performance, with operating revenue of 3.728 billion yuan, a year-on-year increase of 18.85%; net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%; net profit excluding non-recurring gains and losses of 511 million yuan, a year-on-year increase of 44.98%; basic earnings per share of 1.23 yuan/share. It plans to distribute a cash dividend of 6.20 yuan for every 10 shares. The main business revenue of the pharmaceutical industry, medical services, and pharmaceutical commerce increased by 17.82%, 30.15%, and 14.81% year-on-year, respectively"
datetime: "2025-04-02T12:13:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234218976.md)
  - [en](https://longbridge.com/en/news/234218976.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234218976.md)
---

# MYL released its 2024 annual performance, with a net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%

According to the Zhitong Finance APP, MYL (600993.SH) released its annual report for 2024, with an operating income of 3.728 billion yuan, a year-on-year increase of 18.85%; net profit attributable to shareholders of the listed company was 528 million yuan, a year-on-year increase of 19.14%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 511 million yuan, a year-on-year increase of 44.98%; basic earnings per share were 1.23 yuan/share. It is proposed to distribute a cash dividend of 6.20 yuan (including tax) for every 10 shares.

In 2024, the main business income of the pharmaceutical industry was 2.161 billion yuan, a year-on-year increase of 17.82%. The main business income of medical services was 449 million yuan, a year-on-year increase of 30.15%. The main business income of pharmaceutical commerce was 1.249 billion yuan, a year-on-year increase of 14.81%

### Related Stocks

- [600993.CN](https://longbridge.com/en/quote/600993.CN.md)

## Related News & Research

- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [LucidSound Introduces LS500 Wireless Gaming Headset, Built for All-Day Comfort and Seamless Play Across Devices](https://longbridge.com/en/news/286964121.md)
- [14:57 ETSahlen's Unveils "Firecracker" Hot & Spicy Hot Dog for America's 250th Celebration](https://longbridge.com/en/news/287107416.md)
- [13:00 ETBucked Up® Launches Summer Lemonades: Three Limited Edition Pre-Workout Flavors Built for the Season](https://longbridge.com/en/news/287099042.md)
- [Lytica Launches Supplier Intelligence to Modernize Buyer-Supplier Dynamics in Electronics Procurement](https://longbridge.com/en/news/286921721.md)